Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fruquintinib - HUTCHMED

Next Previous
X
Search
Drug Profile

Fruquintinib - HUTCHMED

Alternative Names: Aiyoute; Elunate; FRUZAQLA; HMPL-013; TAK-113

Latest Information Update: 26 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer BeiGene; Eli Lilly and Company; Genor Biopharma; Hutchison MediPharma; HUTCHMED; Shanghai Junshi Biosciences
  • Class Antineoplastics; Benzofurans; Quinazolines; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Colorectal cancer
  • Preregistration Endometrial cancer; Gastric cancer
  • Phase III Non-small cell lung cancer
  • Phase II/III Renal cell carcinoma
  • Phase II Solid tumours
  • Phase I/II Triple negative breast cancer

Most Recent Events

  • 21 Jun 2024 Registered for Colorectal cancer (In the elderly, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in European Union (PO)
  • 31 May 2024 Adverse event data from the phase Ib/II FRUSICA-1 trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 31 May 2024 Pooled efficacy and adverse events data from the phase III FRESCO-2 and FRESCO trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top